NASDAQ:ABCM Abcam (ABCM) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ABCM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.99▼$23.9950-Day Range$23.07▼$23.9952-Week Range$12.48▼$25.32Volume3,300 shsAverage Volume3.08 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsHeadlinesOwnershipShort InterestSocial Media Get Abcam alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Abcam Stock (NASDAQ:ABCM)Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… ABCM Stock News HeadlinesFebruary 27, 2024 | seekingalpha.comTracking George Soros's 13F Portfolio - Q4 2023 UpdateJanuary 18, 2024 | seekingalpha.comHeadwaters Capital Q4 2023 Investor LetterMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.December 8, 2023 | finance.yahoo.comAbcam plc (ABCM) Interactive Stock Chart - Yahoo FinanceNovember 17, 2023 | markets.businessinsider.comAbcam-Danaher Deal Receives All Identified Clearances - Quick FactsNovember 15, 2023 | finance.yahoo.comHere’s Headwaters Capital’s Perspective on Abcam plc (ABCM) AcquisitionNovember 6, 2023 | tmcnet.comShareholders of Abcam Approve Proposed Acquisition by DanaherNovember 1, 2023 | benzinga.comStatement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaignMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.November 1, 2023 | finanznachrichten.deAbcam plc: Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of AbcamOctober 23, 2023 | stockhouse.comLeading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of AbcamOctober 19, 2023 | finance.yahoo.comShe Blinded Me with Science – ISS Makes Schoolboy Error on Abcam DealOctober 17, 2023 | finance.yahoo.comLeading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation’s Proposed Acquisition of AbcamOctober 16, 2023 | markets.businessinsider.comJonathan Milner Issues Statement Responding to ISS ReportOctober 16, 2023 | msn.comAbcam holders should vote for sale to Danaher, proxy adviser ISS says (update)October 16, 2023 | finance.yahoo.comJonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the CompanyOctober 9, 2023 | markets.businessinsider.comAbcam (ABCM) Gets a Hold from RBC CapitalOctober 5, 2023 | msn.comGMED or ABCM: Which Is the Better Value Stock Right Now?October 5, 2023 | finanznachrichten.deAbcam plc: Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per ShareSeptember 21, 2023 | finance.yahoo.comHeadwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – ExclusiveSeptember 15, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisition (update)September 14, 2023 | benzinga.comAbcam plc Statement on Dr. Jonathan Milner's AnnouncementSeptember 14, 2023 | msn.comAbcam holder, founder Jonathan Milner opposes Danaher acquisitionAugust 31, 2023 | finance.yahoo.comAbcam plc Interim Results for the Six-Month Period Ended 30 June 2023August 30, 2023 | msn.comAbcam cut to market perform at Leerink, sees no antitrust riskAugust 29, 2023 | msn.comAbcam deal price may have been hurt by antitrust concerns - report (update)August 29, 2023 | benzinga.comABCAM INVESTOR ALERT by the Former Attorney...See More Headlines Receive ABCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ABCM CUSIPN/A CIK1492074 Webwww.abcam.com Phone44-0-12-2369-6000FaxN/AEmployees1,760Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside-4.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio54.52 P/E Growth2.19Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.35 Quick Ratio1.00 Sales & Book Value Annual Sales$379.70 million Price / Sales14.49 Cash Flow$0.60 per share Price / Cash Flow40.17 Book Value$3.92 per share Price / Book6.12Miscellaneous Outstanding Shares229,272,000Free Float213,842,000Market Cap$5.50 billion OptionableNot Optionable Beta0.86 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Alan Thomas Hirzel BS (Age 55)M.B.A., M.S., CEO & Executive Director Comp: $1.18MMr. Michael Shaun Baldock B.A. (Age 59)CFO & Director Comp: $876.48kMarc Leigh Russell PerkinsGeneral Counsel & Company SecretaryEmma SceatsSenior Vice President of Sales & MarketingMr. Nick SkinnerSenior Vice President of Human ResourcesMs. Alejandra Solache Ph.D.Senior Vice President of Research & DevelopmentMr. John BakerSenior Vice President of Supply Chain & ManufacturingJuan Carlos SacristanSenior Vice President of Data & DigitalMore ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBImmunoGenNASDAQ:IMGNSoleno TherapeuticsNASDAQ:SLNOBlueprint MedicinesNASDAQ:BPMCOption Care HealthNASDAQ:OPCHView All CompetitorsInstitutional OwnershipBluefin Capital Management LLCSold 555,000 shares on 2/16/2024Ownership: 0.000%Citadel Advisors LLCSold 15,000 shares on 2/15/2024Ownership: 0.000%HAP Trading LLCSold 71,200 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions ABCM Stock Analysis - Frequently Asked Questions Should I buy or sell Abcam stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares. View ABCM analyst ratings or view top-rated stocks. What is Abcam's stock price target for 2024? 5 brokers have issued 12-month price targets for Abcam's shares. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's stock price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.1%. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts. What ETFs hold Abcam's stock? ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).ProShares Ultra Nasdaq Biotechnology (BIB). When did Abcam IPO? Abcam (ABCM) raised $149 million in an initial public offering on Thursday, October 22nd 2020. The company issued 9,000,000 shares at a price of $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair acted as the underwriters for the IPO. Who are Abcam's major shareholders? Abcam's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bluefin Capital Management LLC (0.00%), HAP Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). This page (NASDAQ:ABCM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.